Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for the Treatment of Ocular Diseases

HOUSTON and SAN DIEGO, June 1, 2021 /PRNewswire/ — Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-mediated gene therapies for the treatment of ocular diseases, and Hopstem Biotechnology, the leading human induced pluripotent stem cell (hiPSC)…

About the Author

has written 38945 stories on this site.

Copyright © 2010 Business and Corporate News.